Development potential of rifalazil.
Rifalazil represents a new generation of ansamycins that contain a unique four-ring structure. Originally rifalazil was developed as a therapeutic agent to replace rifampin as part of a multiple drug regimen in the treatment of tuberculosis. As a result of its superior antimicrobial activity and high intracellular levels, rifalazil has potential to treat indications caused by the intracellular pathogen, Chlamydia trachomatis, which causes non-gonococcal urethritis and cervicitis, often leading to pelvic inflammatory disease. Rifalazil also has potential to treat the related microorganism, Chlamydia pneumoniae, which may be involved in chronic inflammatory processes thought to be partly responsible for atherosclerosis. Due to its favourable antimicrobial spectrum and other positive attributes, rifalazil may also prove valuable in the treatment of gastric ulcer disease, caused by Helicobacter pylori, and antibiotic-associated colitis, the result of toxin production following the growth of Clostridium difficile in the colon. The potential value of rifalazil in the treatment of these indications will be assessed in human clinical trials.
Rothstein
David M
DM
ActivBiotics, Inc., 198 Broadway, Cambridge, MA 02139, USA. drothstein@activbiotics.com
Hartman
Arthur D
AD
Cynamon
Michael H
MH
Eisenstein
Barry I
BI
D000818:Animals; D000900:Anti-Bacterial Agents / Q000737:chemistry / Q000493:pharmacokinetics; D003141:Communicable Diseases / Q000188:drug therapy / Q000378:metabolism; D006801:Humans; D008826:Microbial Sensitivity Tests / Q000706:statistics & numerical data; D012294:Rifamycins / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use*; D013678:Technology, Pharmaceutical / Q000379:methods* / Q000639:trends
D000900:Anti-Bacterial Agents; D012294:Rifamycins; C068980:KRM 1648